BeOne Medicines (BEIGF) Total Debt Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Total Debt Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn | -2.50% |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn | -4.39% |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn | 52.27% |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 15.32% |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | 2.26% |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | 8.51% |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | -17.14% |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | - |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 12.42% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.42% |
| Mar 31, 2026 | 16.78% |
| Dec 31, 2025 | -45.48% |
| Sep 30, 2025 | 133.93% |
| Jun 30, 2025 | -7.95% |
| Mar 31, 2025 | -9.98% |
| Dec 31, 2024 | 111.01% |
| Sep 30, 2024 | 97.97% |
| Jun 30, 2024 | 64.99% |
| Mar 31, 2024 | 110.20% |
| Dec 31, 2023 | 64.65% |
| Sep 30, 2023 | -18.22% |
| Jun 30, 2023 | 11.05% |
| Mar 31, 2023 | -19.85% |
| Dec 31, 2022 | -14.54% |
| Sep 30, 2022 | 0.94% |
| Jun 30, 2022 | -10.12% |
| Mar 31, 2022 | 1.83% |
| Dec 31, 2021 | -26.24% |
| Sep 30, 2021 | 218.81% |